Sperling, Jens

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Roller, Jonas"],["dc.contributor.author","Malter, Markus M."],["dc.contributor.author","Keller, Kira"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Glanemann, Matthias"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Sperling, Jens"],["dc.date.accessioned","2020-12-10T18:38:54Z"],["dc.date.available","2020-12-10T18:38:54Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s12885-019-6135-x"],["dc.identifier.eissn","1471-2407"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16951"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77472"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","555"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","562"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Schaefer, Thilo"],["dc.contributor.author","Benz-Weisser, Anna"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Scheuer, Claudia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schilling, Martin Karl"],["dc.contributor.author","Menger, Michael D."],["dc.date.accessioned","2018-11-07T09:26:19Z"],["dc.date.available","2018-11-07T09:26:19Z"],["dc.date.issued","2013"],["dc.description.abstract","Systemic chemotherapy still represents the gold standard in the treatment of irresectable colorectal liver metastases. Modern anticancer agents like the monoclonal antibody cetuximab have improved the outcome of patients in clinical studies. As hepatic arterial infusion (HAI) is capable to potentially increase the anticancer effect of cytostatics, we herein studied whether HAI of cetuximab (CE) as a single agent or in combination with oxaliplatin (OX) exerts increased anticancer effects compared to the systemic application (SYS) of the drugs. WAG/Rij rats were randomized to eight groups and underwent 10 days after subcapsular hepatic tumor implantation either HAI or SYS of CE, OX, or the combination of both agents (CE + OX). Saline-treated animals served as controls. Tumor volume was measured at days 10 and 13 using three-dimensional ultrasound. On day 13, liver and tumor tissue was sampled for histological and immunohistochemical analysis. In controls, the tumor volume significantly increased from day 10 to 13. Application of OX alone via HAI or SYS did not inhibit tumor growth compared to controls. SYS of CE or CE + OX did also not reduce tumor growth. In contrast, HAI of CE and CE + OX significantly inhibited tumor growth. HAI of CE significantly reduced tumor vascularization as measured by the number of platelet endothelial cell adhesion molecule-1-positive cells and significantly increased the number of apoptotic tumor cells as measured by the cellular caspase-3 expression. HAI of CE and CE + OX reduces tumor growth of colorectal rat liver metastases involving the inhibition of angiogenesis and induction of tumor cell apoptosis."],["dc.identifier.doi","10.1007/s00384-012-1617-1"],["dc.identifier.isi","000318368300014"],["dc.identifier.pmid","23242249"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10946"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30274"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","447"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","455"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Brandhorst, David"],["dc.contributor.author","Schäfer, Thilo"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Benz-Weißer, Anna"],["dc.contributor.author","Scheuer, Claudia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schilling, Martin"],["dc.contributor.author","Menger, Michael"],["dc.date.accessioned","2019-07-09T11:39:49Z"],["dc.date.available","2019-07-09T11:39:49Z"],["dc.date.issued","2012"],["dc.description.abstract","Colorectal carcinoma is, through to its high rate of liver metastasis (mCRC), the second most cause of cancer death worldwide. Tumor resection represents the only potential cure. In cases of unresectable disease systemic chemotherapy (sCHT) remains the therapy of choice. Modern sCHT regimens including biological agents can induce tumor response that leads to curative surgery of initially unresectable mCRC. However, liver-directed therapy via hepatic arterial infusion (HAI) may produce higher response rates than sCHT. Herein we studied whether a HAI of cetuximab (CE) plus bevacizumab (BE) with or without oxaliplatin (OX) can inhibit tumor growth in a rat model. WAG/Rij rats underwent subcapsular hepatic tumor implantation. After 10 days animals received either HAI or sCHT of CE plus BE, OX or all three drugs. Saline-treated animals served as controls. Tumor growth was estimated at day 10 and 13. On day 13 liver and tumor tissue was studied histologically and immunohistochemically. In controls the tumors grew about 50 %. OX alone was not capable of inhibiting tumor growth. In contrast, CE plus BE given as HAI significantly reduced tumor growth compared to sCHT (p < 0.05). HAI of CE plus BE combined with OX yielded an even more pronounced inhibition of tumor growth. Immunohistochemistry revealed a decreased tumor cell proliferation and tumor vascularization. The present study demonstrates that HAI of CE plus BE is effective to inhibit tumor growth. This effect is even more pronounced in combination with OX. Systemic application of these agents cannot achieve comparable effects."],["dc.identifier.doi","10.1007/s10585-012-9550-9"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10342"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58044"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","198"],["dc.bibliographiccitation.journal","World Journal of Surgical Oncology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Justinger, Christoph"],["dc.contributor.author","Schuld, Jochen"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Seidel, Roland"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:38:11Z"],["dc.date.available","2018-11-07T09:38:11Z"],["dc.date.issued","2014"],["dc.description.abstract","Intra- or extrahepatic cholangiocarcinomas are the second most common primary liver malignancies behind hepatocellular carcinoma. Whereas the incidence for intrahepatic cholangiocarcinoma is rising, the occurrence of extrahepatic cholangiocarcinoma is trending downwards. The treatment of choice for intrahepatic cholangiocarcinoma remains liver resection. However, a case of liver resection after selective internal radiation therapy in order to treat a recurrent intrahepatic cholangiocarcinoma in a transplant liver is unknown in the literature so far. Herein, we present a case of a patient undergoing liver transplantation for Wilson's disease with an accidental finding of an intrahepatic cholangiocarcinoma within the explanted liver. Due to a recurrent intrahepatic cholangiocarcinoma after liver transplantation, a selective internal radiation therapy with yttrium-90 microspheres was performed followed by right hemihepatectomy. Four years later, the patient is tumor-free and in a healthy condition."],["dc.identifier.doi","10.1186/1477-7819-12-198"],["dc.identifier.isi","000339373600001"],["dc.identifier.pmid","24980217"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10439"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33016"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7819"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Intrahepatic cholangiocarcinoma in a transplant liver - selective internal radiation therapy followed by right hemihepatectomy: report of a case"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","323"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","332"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Senger, Sebastian"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Oberkircher, Barbara"],["dc.contributor.author","Schilling, Martin K."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Ziemann, Christian"],["dc.date.accessioned","2020-12-10T14:11:27Z"],["dc.date.available","2020-12-10T14:11:27Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s10585-017-9852-z"],["dc.identifier.eissn","1573-7276"],["dc.identifier.issn","0262-0898"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71078"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Portal branch ligation does not counteract the inhibiting effect of temsirolimus on extrahepatic colorectal metastatic growth"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","587"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Surgical Research"],["dc.bibliographiccitation.lastpage","594"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Gittler, Anika"],["dc.contributor.author","Benz-Weisser, Anna"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:17:19Z"],["dc.date.available","2018-11-07T09:17:19Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Hepatic arterial infusion (HAI) of specific anti-tumor drugs can be more effective compared with systemic drug application. Herein, we studied whether HAI of temsirolimus is effective to inhibit tumor growth of colorectal liver metastases after liver resection. Materials and methods: Twenty-four Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats were randomized to four groups and underwent subcapsular implantation of CC531 colorectal cancer cells in the left liver lobe. In two groups, a 70% liver resection (Phx) was performed simultaneously. After 10 d, animals received either a HAI of temsirolimus (CCI-779) or saline solution (controls). Tumor growth was determined on d 10 and 13 using three-dimensional ultrasound. On d 13, tumor tissue was removed for histologic and immunohistochemical analysis. Results: Sham controls revealed a tumor growth of similar to 40% from d 10 to d 13. HAI of temsirolimus completely inhibited this tumor growth. Controls with Phx showed a tumor growth of > 60%. In contrast, HAI of temsirolimus in Phx animals did not only inhibit tumor growth but was even capable of decreasing the tumor size by similar to 8%. Immunohistochemical analysis of the tumors showed a decreased proliferation rate and an increased cleaved caspase-3 activity, which was associated with a significant reduction of platelet endothelial cell adhesion molecule (PECAM)-1-positive cells after HAI of temsirolimus. Conclusions: HAI of temsirolimus inhibits tumor growth of CC531 colorectal liver metastases even if a growth-stimulating procedure like Phx is performed. Inhibition of tumor growth is provided by a decrease of tumor vascularization associated with an inhibition of tumor cell proliferation and an induction of tumor cell apoptosis. (C) 2013 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.jss.2013.06.005"],["dc.identifier.isi","000326938500042"],["dc.identifier.pmid","23845871"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28136"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Academic Press Inc Elsevier Science"],["dc.relation.issn","1095-8673"],["dc.relation.issn","0022-4804"],["dc.title","Hepatic arterial infusion of temsirolimus inhibits tumor growth of colorectal rat liver metastases even after a growth stimulating procedure like liver resection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","313"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","321"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Sperling, Jens"],["dc.contributor.author","Ziemann, Christian"],["dc.contributor.author","Gittler, Anika"],["dc.contributor.author","Benz-Weisser, Anna"],["dc.contributor.author","Menger, Michael D."],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:59:04Z"],["dc.date.available","2018-11-07T09:59:04Z"],["dc.date.issued","2015"],["dc.description.abstract","Portal branch ligation (PBL) can be performed before major hepatic resection of colorectal liver metastases (mCRC) to increase the remnant liver mass. However, PBL may also stimulate mCRC growth through hepatic arterial hyperperfusion and growth factor release. Herein, we studied whether hepatic arterial infusion (HAI) of the mTOR-inhibitor temsirolimus (Tem) is capable of inhibiting the growth of colorectal liver metastases after PBL. WAG/Rij rats were randomized to four groups (n = 6 each) and underwent subcapsular implantation of 5 x 10(5) CC531 cells into the left liver lobe. The animals of two groups underwent simultaneous PBL of the tumour bearing liver lobe. Ten days later animals underwent a HAI either of temsirolimus (Tem and PBL Tem) or saline solution (Sham and PBL Sham). Tumour size was analyzed at days 10 and 13 using three-dimensional ultrasound. In Sham controls tumour volume increased by 43 %. After PBL Sham tumour volume increased by 52 %. In contrast, in animals undergoing HAI of temsirolimus the tumour growth was not only completely inhibited, but tumour volume was found decreased, irrespective of PBL. After HAI of temsirolimus immunohistochemistry revealed an increased cleaved caspase-3 activity, indicating stimulation of apoptotic cell death. In parallel temsirolimus treatment was associated with a significant reduction of PECAM-1 positive cells within the tumour tissue, implying a reduced tumour vascularisation. HAI of temsirolimus is capable of inhibiting the growth of CC531 colorectal rat liver metastases also after PBL."],["dc.identifier.doi","10.1007/s10585-015-9707-4"],["dc.identifier.isi","000352642000002"],["dc.identifier.pmid","25693517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37505"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-7276"],["dc.relation.issn","0262-0898"],["dc.title","Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]